On 26 June 2019 the Federal Council submitted a draft amendment to the Narcotics Act (SR 812121) for consultation that aims to facilitate patients' access to cannabis-based treatments.
The revised act would allow patients to obtain direct medical prescriptions for cannabis-based treatments with a tetrahydrocannabinol content of more than 1% without the need for an exceptional licence from the Federal Office of Public Health.
If the draft amendment is approved, the Narcotics Act's existing prohibition on placing medical cannabis on the Swiss market would be repealed.
The cultivation, processing and trading of medicinal cannabis would thereby become legal within the framework of a control system managed by Swissmedic.(1)
(1) For further information, see here.
This article was first published by the International Law Office, a premium online legal update service for major companies and law firms worldwide. Register for a free subscription.